BioMed Research International / 2014 / Article / Tab 5

Research Article

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

Table 5

The associations between BMP-4 polymorphisms and PFS and OS of NSCLC patients undergoing chemotherapy.

BMP-4 polymorphismsMedian PFS, mo
(95% CI)
Log-rank Median OS, mo
(95% CI)

−5826G > A
 GG8.4 (4.5–10.2)0.65917.5 (7.6–22.4)0.364
 GA7.9 (5.0–9.1)18.1 (7.7–20.8)
 AA8.2 (4.9–7.7)17.1 (6.9–19.5)
6007C > T
 TT6.6 (5.5–8.2)0.49213.5 (5.6–18.8)0.002
 CT7.0 (4.7–11.5)14.7 (6.8–19.4)
 CC8.9 (5.4–12.1)18.4 (11.8–19.5)
BMP-4 expression
 Low10.0 (8.1–17.5)<0.00118.6 (9.9–23.2)<0.001
 High6.2 (4.9–10.7)9.8 (5.1–13.2)

Adjusted with age, sex, smoke status, histology, stage, and chemotherapy agents.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.